Literature DB >> 18609687

Inflammatory bowel disease in rats: bacterial and chemical interaction.

Inaya-Abdallah Hajj Hussein1, Rania Tohme, Kassem Barada, Mostafa Hassan Mostafa, Jean-Noel Freund, Rosalyn A Jurjus, Walid Karam, Abdo Jurjus.   

Abstract

AIM: To develop a novel model of colitis in rats, using a combination of iodoacetamide and enteropathogenic E. coli (EPEC), and to elucidate the pathophysiologic processes implicated in the development of ulcerative colitis (UC).
METHODS: Male Sprague-Dawley rats (n = 158) were inoculated intrarectally on a weekly basis with 4 different combinations: (a) 1% methylcellulose (MC), (b) 100 microL of 6% iodoacetamide (IA) in 1% MC, (c) 200 microL containing 4 x 10(8) colony factor units (CFU) of EPEC, and (d) combined treatment of (IA) followed by bacteria (B) after 2 d. Thirty days post treatment, each of the four groups was divided into two subgroups; the inoculation was stopped for one subgroup and the other subgroup continued with biweekly inoculation until the end of the experiment. Colitis was evaluated by the clinical course of the disease, the macroscopic and microscopic alterations, activity of myeloperoxidase (MPO), and by TNF-alpha gene expression.
RESULTS: Findings indicative of UC were seen in the combined treatment (IA + B) as well as the IA continued treatment groups: the animals showed slow rate of increase in body weight, diarrhea, bloody stools, high colonic ulcer score, as well as histological alterations characteristic of UC, with an extensive inflammatory reaction. During the course of the experiment, the MPO activity was consistently elevated and the TNF-alpha gene expression was upregulated compared to the control animals.
CONCLUSION: The experimental ulcerative colitis model used in the present study resembles, to a great extent, the human disease. It is reproducible with characteristics indicative of chronicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18609687      PMCID: PMC2725342          DOI: 10.3748/wjg.14.4028

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  39 in total

Review 1.  The development of animal models of inflammatory bowel disease.

Authors:  L Mayer
Journal:  Int Rev Immunol       Date:  2000       Impact factor: 5.311

Review 2.  Bacteria as the cause of ulcerative colitis.

Authors:  M Campieri; P Gionchetti
Journal:  Gut       Date:  2001-01       Impact factor: 23.059

Review 3.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

4.  Interactions between commensal intestinal bacteria and the immune system.

Authors:  Andrew J Macpherson; Nicola L Harris
Journal:  Nat Rev Immunol       Date:  2004-06       Impact factor: 53.106

5.  Disrupted barrier function through epithelial cell apoptosis.

Authors:  Joerg-Dieter Schulzke; Christian Bojarski; Sebastian Zeissig; Frank Heller; Alfred H Gitter; Michael Fromm
Journal:  Ann N Y Acad Sci       Date:  2006-08       Impact factor: 5.691

6.  Experimental colitis increases small intestine permeability in the rat.

Authors:  W Fries; E Mazzon; S Squarzoni; A Martin; D Martines; A Micali; G C Sturniolo; S Citi; G Longo
Journal:  Lab Invest       Date:  1999-01       Impact factor: 5.662

7.  Small intestinal histochemical and histological changes in ulcerative colitis.

Authors:  N Jankey; L A Price
Journal:  Gut       Date:  1969-04       Impact factor: 23.059

8.  Cloning and characterization of the eae gene of enterohaemorrhagic Escherichia coli O157:H7.

Authors:  J Yu; J B Kaper
Journal:  Mol Microbiol       Date:  1992-02       Impact factor: 3.501

9.  Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models.

Authors:  J E Krawisz; P Sharon; W F Stenson
Journal:  Gastroenterology       Date:  1984-12       Impact factor: 22.682

10.  Epithelia under metabolic stress perceive commensal bacteria as a threat.

Authors:  Aisha Nazli; Ping-Chang Yang; Jennifer Jury; Kathryn Howe; James L Watson; Johan D Söderholm; Philip M Sherman; Mary H Perdue; Derek M McKay
Journal:  Am J Pathol       Date:  2004-03       Impact factor: 4.307

View more
  6 in total

Review 1.  Dismicrobism in inflammatory bowel disease and colorectal cancer: changes in response of colocytes.

Authors:  Giovanni Tomasello; Pietro Tralongo; Provvidenza Damiani; Emanuele Sinagra; Benedetto Di Trapani; Marie Noelle Zeenny; Inaya Hajj Hussein; Abdo Jurjus; Angelo Leone
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

Review 2.  Spontaneous and transgenic rodent models of inflammatory bowel disease.

Authors:  Susan Prattis; Abdo Jurjus
Journal:  Lab Anim Res       Date:  2015-06-26

Review 3.  Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: The links.

Authors:  Abdo Jurjus; Assad Eid; Sahar Al Kattar; Marie Noel Zeenny; Alice Gerges-Geagea; Hanine Haydar; Anis Hilal; Doreid Oueidat; Michel Matar; Jihane Tawilah; Inaya Hajj Hussein; Pierre Schembri-Wismayer; Francesco Cappello; Giovanni Tomasello; Angelo Leone; Rosalyn A Jurjus
Journal:  BBA Clin       Date:  2015-11-05

4.  A novel therapeutic approach to colorectal cancer in diabetes: role of metformin and rapamycin.

Authors:  Alice Gerges Geagea; Manfredi Rizzo; Abdo Jurjus; Francesco Cappello; Angelo Leone; Giovanni Tomasello; Céline Gracia; Sahar Al Kattar; Liliane Massaad-Massade; Assaad Eid
Journal:  Oncotarget       Date:  2019-02-12

5.  The effect of bifid triple viable on immune function of patients with ulcerative colitis.

Authors:  Guohua Li; Sheng Zeng; Wangdi Liao; Nonghua Lv
Journal:  Gastroenterol Res Pract       Date:  2012-08-15       Impact factor: 2.260

6.  Characterization of Rat ILCs Reveals ILC2 as the Dominant Intestinal Subset.

Authors:  Ahmed Abidi; Thomas Laurent; Gaëlle Bériou; Laurence Bouchet-Delbos; Cynthia Fourgeux; Cédric Louvet; Raja Triki-Marrakchi; Jeremie Poschmann; Régis Josien; Jérôme Martin
Journal:  Front Immunol       Date:  2020-02-19       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.